SCHEMBL6085754

SCHEMBL6085754

Cc1ccc2nc(-c3c[nH]nc3-c3cccc(NC(=O)CCC(N)=O)c3)oc2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.58
RAB9A P51151 3/20 0.58
MAPT P10636 8/20 0.53
TP53 P04637 7/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
HSD17B10 Q99714 6/20 0.50
KDM4E B2RXH2 6/20 0.50
P2RY14 Q15391 4/20 0.49
ALDH1A1 P00352 3/20 0.49
HPGD P15428 3/20 0.49
GAA P10253 2/20 0.49
CETP P11597 1/20 0.49
USP2 O75604 3/20 0.47
TSHR P16473 2/20 0.47
POLB P06746 2/20 0.47
HTT P42858 1/20 0.47
KMT2A Q03164 1/20 0.47
THRB P10828 2/20 0.46
PKM P14618 1/20 0.46
MAPK1 P28482 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6084095 0.89 HSD17B10 (0.48) NPC1RAB9AMAPTTP53SMN1; SMN2
SCHEMBL6085490 0.87 P2RY14 (0.67) NPC1RAB9AMAPTTP53SMN1; SMN2
SCHEMBL6085535 0.87 NPC1 (0.59) NPC1RAB9AMAPTTP53SMN1; SMN2
SCHEMBL6083537 0.87 P2RY14 (0.61) NPC1RAB9AMAPTTP53SMN1; SMN2
SCHEMBL6083677 0.87 NPC1 (0.57) NPC1RAB9AMAPTTP53SMN1; SMN2
SCHEMBL6085544 0.86 NPC1 (0.56) NPC1RAB9AMAPTTP53SMN1; SMN2
SCHEMBL6084746 0.85 NPC1 (0.56) NPC1RAB9AMAPTTP53SMN1; SMN2
SCHEMBL6086751 0.84 NPC1 (0.58) NPC1RAB9AMAPTTP53SMN1; SMN2
SCHEMBL6083799 0.84 HSD17B10 (0.48) NPC1RAB9AMAPTTP53SMN1; SMN2
SCHEMBL6085394 0.84 MAPT (0.58) NPC1RAB9AMAPTTP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US claimed
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US disclosed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP disclosed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 NPC1 4031/4885RAB9A 2584/4885MAPT 801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.